1. negative diagnostic test for sars-cov2 associated with acute flu-like symptoms (patients with a negative test taken early and becoming positive a few days later are eligible, as long as they are \< 07 days from the onset of flu-like symptoms); 2. patients with an acute respiratory condition compatible with covid-19 treated in the primary care network and with a decision to be hospitalized; 3. patients with acute respiratory symptoms due to other causes; 4. dyspnea secondary to other acute and chronic respiratory causes or infections (e.g. decompensated copd, acute bronchitis, pneumonia other than viral, primary pulmonary arterial hypertension); 5. patients requiring hospitalization due to covid-19 or spo2 ≤ 93%. 6. exclusion criteria applicable to the 7-day treatment arms: 1. abnormal findings on physical examination: respiratory rate ≥ 25 irm; blood pressure \< 90/ 60 mmhg or \> 160/ 100 mmhg; weight \< 45 kg; recent episodes of vomiting in the last 24 hours or diarrhea \> 3 episodes in the last 24 hours or serum potassium below 3.5 meq/l. 2. serious injury to any organ that requires resuscitation and continuous treatment. 3. use of chronic systemic corticosteroid therapy with prednisone equivalent doses of \> 40 mg/day 4. ongoing immunosuppressive treatment 5. history of known pulmonary arterial hypertension or pulmonary fibrosis 6. patients previously vaccinated with two doses for sars-cov-2, with the last dose administered less than 180 days after screening; patients with a single dose of janssen sars-cov-2 vaccine received (except janssen vaccine) and unvaccinated patients can participate regardless of the period. 7. use of serotonin reuptake inhibitors (all) 8. patients vaccinated for sars-cov-2 (complete vaccination - 02 doses) within 06 months of the last dose before randomization or patients who received a "booster" dose at any time before randomization. 9. for any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or concomitant intake of medication prohibited for its use. 10. enrolled in other clinical trials with unregistered medicines or with a registered medicine that may interact with any of the study pis or contraindicated as concomitant treatment in the last 3 months before screening. 7. exclusion criteria applicable to the 10-day treatment arm: a. chronic use of serotonin reuptake inhibitors other than sertraline b. chronic use of corticosteroid therapy with prednisone equivalent doses of \> 40 mg/day 8. exclusion criteria applicable to the 14-day treatment arm: patients with phenylketonuria; 9. continued use of monoamine oxidation inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazid, moclobemide; 10. patients with severe psychiatric disorders - schizophrenia, uncontrolled bipolar disorders, major depression with suicidal ideation. 11. pregnant or breastfeeding patients; 12. history of severe ventricular cardiac arrhythmia (ventricular tachycardia, recovered ventricular fibrillation patients) or long qt syndrome; 13. known history of decompensated heart failure (nyha iii or iv), recent myocardial infarction (event \< 90 days from screening), unstable angina, recent coronary bypass surgery (procedure \< 90 days from screening), recent stroke ( event \< 90 days from screening), symptomatic carotid disease, or mitral or aortic stenosis of moderate to severe intensity; 14. surgical procedure or hospitalization planned (for other indications) to occur during treatment or up to 5 days after the last dose of study medication; 15. current daily and/or uncontrolled alcohol consumption, which in the investigator's view could compromise participation in the study; 16. history of seizures in the last month or uncontrolled seizures; 17. clinical history of moderate to severe hepatic impairment or liver cirrhosis with child-pugh classification c; 18. patients with known severe degenerative neurological diseases and/or serious mental illnesses as assessed by the investigator; 19. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. any clinical conditions, including psychiatric conditions, which in the investigator's view could be an impediment to the use of research medications; 21. known hypersensitivity and/or intolerance to spirulin platensis, budesonide, fluvoxamine and fluoxetine; 22. use of medications which have a known interaction with spirulin platensis, budesonide, fluvoxamine and fluoxetine; 23. inability to use the medications and formulations provided for in this research;

1. negative diagnostic test for sars-cov2 associated with acute flu-like symptoms (patients with a negative test taken early and becoming positive a few days later are eligible, as long as they are \< 07 days from the onset of flu-like symptoms); 2. patients with an acute respiratory condition compatible with covid-19 treated in the primary care network and with a decision to be hospitalized; 3. patients with acute respiratory symptoms due to other causes; 4. dyspnea secondary to other acute and chronic respiratory causes or infections (e.g. decompensated copd, acute bronchitis, pneumonia other than viral, primary pulmonary arterial hypertension); 5. patients requiring hospitalization due to covid-19 or spo2 ≤ 93%. 6. exclusion criteria applicable to the 7-day treatment arms: 1. abnormal findings on physical examination: respiratory rate ≥ 25 irm; blood pressure \< 90/ 60 mmhg or \> 160/ 100 mmhg; weight \< 45 kg; recent episodes of vomiting in the last 24 hours or diarrhea \> 3 episodes in the last 24 hours or serum potassium below 3.5 meq/l. 2. serious injury to any organ that requires resuscitation and continuous treatment. 3. use of chronic systemic corticosteroid therapy with prednisone equivalent doses of \> 40 mg/day 4. ongoing immunosuppressive treatment 5. history of known pulmonary arterial hypertension or pulmonary fibrosis 6. patients previously vaccinated with two doses for sars-cov-2, with the last dose administered less than 180 days after screening; patients with a single dose of janssen sars-cov-2 vaccine received (except janssen vaccine) and unvaccinated patients can participate regardless of the period. 7. use of serotonin reuptake inhibitors (all) 8. patients vaccinated for sars-cov-2 (complete vaccination - 02 doses) within 06 months of the last dose before randomization or patients who received a "booster" dose at any time before randomization. 9. for any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or concomitant intake of medication prohibited for its use. 10. enrolled in other clinical trials with unregistered medicines or with a registered medicine that may interact with any of the study pis or contraindicated as concomitant treatment in the last 3 months before screening. 7. exclusion criteria applicable to the 10-day treatment arm: a. chronic use of serotonin reuptake inhibitors other than sertraline b. chronic use of corticosteroid therapy with prednisone equivalent doses of \> 40 mg/day 8. exclusion criteria applicable to the 14-day treatment arm: patients with phenylketonuria; 9. continued use of monoamine oxidation inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazid, moclobemide; 10. patients with severe psychiatric disorders - schizophrenia, uncontrolled bipolar disorders, major depression with suicidal ideation. 11. pregnant or breastfeeding patients; 12. history of severe ventricular cardiac arrhythmia (ventricular tachycardia, recovered ventricular fibrillation patients) or long qt syndrome; 13. known history of decompensated heart failure (nyha iii or iv), recent myocardial infarction (event \< 90 days from screening), unstable angina, recent coronary bypass surgery (procedure \< 90 days from screening), recent stroke ( event \< 90 days from screening), symptomatic carotid disease, or mitral or aortic stenosis of moderate to severe intensity; 14. surgical procedure or hospitalization planned (for other indications) to occur during treatment or up to 5 days after the last dose of study medication; 15. current daily and/or uncontrolled alcohol consumption, which in the investigator's view could compromise participation in the study; 16. history of seizures in the last month or uncontrolled seizures; 17. clinical history of moderate to severe hepatic impairment or liver cirrhosis with child-pugh classification c; 18. patients with known severe degenerative neurological diseases and/or serious mental illnesses as assessed by the investigator; 19. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. any clinical conditions, including psychiatric conditions, which in the investigator's view could be an impediment to the use of research medications; 21. known hypersensitivity and/or intolerance to spirulin platensis, budesonide, fluvoxamine and fluoxetine; 22. use of medications which have a known interaction with spirulin platensis, budesonide, fluvoxamine and fluoxetine; 23. inability to use the medications and formulations provided for in this research;

negative diagnostic test for sars-cov2 associated with acute flu-like symptoms (patients with a negative test taken early and becoming positive a few days later are eligible, as long as they are < 07 days from the onset of flu-like symptoms); patients with an acute respiratory condition compatible with covid-19 treated in the primary care network and with a decision to be hospitalized; patients with acute respiratory symptoms due to other causes; dyspnea secondary to other acute and chronic respiratory causes or infections (e.g. decompensated copd, acute bronchitis, pneumonia other than viral, primary pulmonary arterial hypertension); patients requiring hospitalization due to covid-19 or spo2 ≤ 93%. exclusion criteria applicable to the 7-day treatment arms: abnormal findings on physical examination: respiratory rate ≥ 25 irm; blood pressure < 90/ 60 mmhg or > 160/ 100 mmhg; weight < 45 kg; recent episodes of vomiting in the last 24 hours or diarrhea > 3 episodes in the last 24 hours or serum potassium below 3.5 meq/l. serious injury to any organ that requires resuscitation and continuous treatment. use of chronic systemic corticosteroid therapy with prednisone equivalent doses of > 40 mg/day ongoing immunosuppressive treatment history of known pulmonary arterial hypertension or pulmonary fibrosis patients previously vaccinated with two doses for sars-cov-2, with the last dose administered less than 180 days after screening; patients with a single dose of janssen sars-cov-2 vaccine received (except janssen vaccine) and unvaccinated patients can participate regardless of the period. use of serotonin reuptake inhibitors (all) patients vaccinated for sars-cov-2 (complete vaccination - 02 doses) within 06 months of the last dose before randomization or patients who received a "booster" dose at any time before randomization. for any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or concomitant intake of medication prohibited for its use. enrolled in other clinical trials with unregistered medicines or with a registered medicine that may interact with any of the study pis or contraindicated as concomitant treatment in the last 3 months before screening. exclusion criteria applicable to the 10-day treatment arm: a. chronic use of serotonin reuptake inhibitors other than sertraline b. chronic use of corticosteroid therapy with prednisone equivalent doses of > 40 mg/day exclusion criteria applicable to the 14-day treatment arm: patients with phenylketonuria; continued use of monoamine oxidation inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazid, moclobemide; patients with severe psychiatric disorders - schizophrenia, uncontrolled bipolar disorders, major depression with suicidal ideation. pregnant or breastfeeding patients; history of severe ventricular cardiac arrhythmia (ventricular tachycardia, recovered ventricular fibrillation patients) or long qt syndrome; known history of decompensated heart failure (nyha iii or iv), recent myocardial infarction (event < 90 days from screening), unstable angina, recent coronary bypass surgery (procedure < 90 days from screening), recent stroke ( event < 90 days from screening), symptomatic carotid disease, or mitral or aortic stenosis of moderate to severe intensity; surgical procedure or hospitalization planned (for other indications) to occur during treatment or up to 5 days after the last dose of study medication; current daily and/or uncontrolled alcohol consumption, which in the investigator's view could compromise participation in the study; history of seizures in the last month or uncontrolled seizures; clinical history of moderate to severe hepatic impairment or liver cirrhosis with child-pugh classification c; patients with known severe degenerative neurological diseases and/or serious mental illnesses as assessed by the investigator; inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; any clinical conditions, including psychiatric conditions, which in the investigator's view could be an impediment to the use of research medications; known hypersensitivity and/or intolerance to spirulin platensis, budesonide, fluvoxamine and fluoxetine; use of medications which have a known interaction with spirulin platensis, budesonide, fluvoxamine and fluoxetine; inability to use the medications and formulations provided for in this research;

negative diagnostic test for sars-cov2 associated with acute flu-like symptoms (patients with a negative test taken early and becoming positive a few days later are eligible, as long as they are < 07 days from the onset of flu-like symptoms); patients with an acute respiratory condition compatible with covid-19 treated in the primary care network and with a decision to be hospitalized; patients with acute respiratory symptoms due to other causes; dyspnea secondary to other acute and chronic respiratory causes or infections (e.g. decompensated copd, acute bronchitis, pneumonia other than viral, primary pulmonary arterial hypertension); patients requiring hospitalization due to covid-19 or spo2 ≤ 93%. exclusion criteria applicable to the 7-day treatment arms: abnormal findings on physical examination: respiratory rate ≥ 25 irm; blood pressure < 90/ 60 mmhg or > 160/ 100 mmhg; weight < 45 kg; recent episodes of vomiting in the last 24 hours or diarrhea > 3 episodes in the last 24 hours or serum potassium below 3.5 meq/l. serious injury to any organ that requires resuscitation and continuous treatment. use of chronic systemic corticosteroid therapy with prednisone equivalent doses of > 40 mg/day ongoing immunosuppressive treatment history of known pulmonary arterial hypertension or pulmonary fibrosis patients previously vaccinated with two doses for sars-cov-2, with the last dose administered less than 180 days after screening; patients with a single dose of janssen sars-cov-2 vaccine received (except janssen vaccine) and unvaccinated patients can participate regardless of the period. use of serotonin reuptake inhibitors (all) patients vaccinated for sars-cov-2 (complete vaccination - 02 doses) within 06 months of the last dose before randomization or patients who received a "booster" dose at any time before randomization. for any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or concomitant intake of medication prohibited for its use. enrolled in other clinical trials with unregistered medicines or with a registered medicine that may interact with any of the study pis or contraindicated as concomitant treatment in the last 3 months before screening. exclusion criteria applicable to the 10-day treatment arm: a. chronic use of serotonin reuptake inhibitors other than sertraline b. chronic use of corticosteroid therapy with prednisone equivalent doses of > 40 mg/day exclusion criteria applicable to the 14-day treatment arm: patients with phenylketonuria; continued use of monoamine oxidation inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazid, moclobemide; patients with severe psychiatric disorders - schizophrenia, uncontrolled bipolar disorders, major depression with suicidal ideation. pregnant or breastfeeding patients; history of severe ventricular cardiac arrhythmia (ventricular tachycardia, recovered ventricular fibrillation patients) or long qt syndrome; known history of decompensated heart failure (nyha iii or iv), recent myocardial infarction (event < 90 days from screening), unstable angina, recent coronary bypass surgery (procedure < 90 days from screening), recent stroke ( event < 90 days from screening), symptomatic carotid disease, or mitral or aortic stenosis of moderate to severe intensity; surgical procedure or hospitalization planned (for other indications) to occur during treatment or up to 5 days after the last dose of study medication; current daily and/or uncontrolled alcohol consumption, which in the investigator's view could compromise participation in the study; history of seizures in the last month or uncontrolled seizures; clinical history of moderate to severe hepatic impairment or liver cirrhosis with child-pugh classification c; patients with known severe degenerative neurological diseases and/or serious mental illnesses as assessed by the investigator; inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; any clinical conditions, including psychiatric conditions, which in the investigator's view could be an impediment to the use of research medications; known hypersensitivity and/or intolerance to spirulin platensis, budesonide, fluvoxamine and fluoxetine; use of medications which have a known interaction with spirulin platensis, budesonide, fluvoxamine and fluoxetine; inability to use the medications and formulations provided for in this research;

diagnostic test for negative sars-cov2 associated with acute flu symptoms (patient with a negative test collected early and becomes positive a few days later is eligible, as long as it is < 07 days since the onset of flu symptoms). patients with an acute respiratory condition compatible with covid-19 treated in the primary care network and with a decision to be hospitalized. patients with acute respiratory symptoms due to other causes. dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated copd, acute bronchitis, pneumonia other than viral, primary pulmonary arterial hypertension). patients requiring hospitalization due to covid-19 or spo2 ≤ 93%. note: patients allocated to the fluvoxamine arm alone may be included if spo2 is below 94%, with no evidence of acute respiratory failure, provided that the attending physician decides to discharge the unit and continue treatment on an outpatient basis. exclusion criteria applicable to injectable medication arms: a. patients on chronic use of prednisone, prednisolone or other corticosteroids with doses > 10 mg/day equivalent to prednisone. exclusion criteria applicable to 07-day treatment arms: abnormal findings on physical examination: respiratory rate ≥ 25 sisters; blood pressure < 90/60 mmhg or > 160/100 mmhg; weight < 45 kg; recent episodes of vomiting within the last 24 hours or recurrent diarrhea or serum potassium below 3.5 meq/l. severe organ damage that requires resuscitation and ongoing treatment. chronic corticosteroid use with equivalent prednisone doses of > 40 mg/day immunosuppressive treatment in progress history of known pulmonary arterial hypertension or pulmonary fibrosis patients who have received a previous dose of sars-cov-2 vaccine use of serotonin reuptake inhibitors (all). exclusion criteria applicable to 10-day treatment arms: chronic use of serotonin reuptake inhibitors other than sertraline chronic corticosteroid use with equivalent prednisone doses of > 40 mg/day; continued use of monoamine oxidative inhibitors (maoi): phenelzine, tranylcypromine, selegiline, isocarboxazid, moclobemide. patients with severe psychiatric disorders - schizophrenia, uncontrolled bipolar disorders, major depression with suicidal ideation. pregnant or breastfeeding patients. history of severe ventricular cardiac arrhythmia (ventricular tachycardia, recovered ventricular fibrillation patients) or long qt syndrome. known history of decompensated heart failure (nyha iii or iv), recent myocardial infarction (event < 90 days of screening), unstable angina, recent coronary bypass surgery (procedure < 90 days of screening), recent stroke ( event < 90 days from screening), symptomatic carotid disease, or moderate to severe mitral or aortic stenosis. surgical procedure or hospitalization planned (for other indications) to occur during treatment or up to 5 days after the last dose of study medication. current daily and/or uncontrolled alcohol consumption, which, in the investigator's view, could compromise participation in the study. history of seizures in the last month or uncontrolled seizures. clinical history of moderate to severe hepatic impairment or hepatic cirrhosis with child-pugh c classification. patients with known serious degenerative neurological diseases and/or serious mental illnesses as assessed by the investigator. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol. any clinical conditions, including psychiatric conditions, which, in the investigator's view, could prevent the use of research drugs. known hypersensitivity and/or intolerance to fluvoxamine, budesonide, pegylated interferon lambda and fluoxetine. use of drugs which have a known interaction with fluvoxamine, budesonide, pegylated interferon lambda and fluoxetine. inability to use the drugs and formulations provided for in this research.

diagnostic test for negative sars-cov2 associated with acute flu symptoms (patient with a negative test collected early and becomes positive a few days later is eligible, as long as it is < 07 days since the onset of flu symptoms). patients with an acute respiratory condition compatible with covid-19 treated in the primary care network and with a decision to be hospitalized. patients with acute respiratory symptoms due to other causes. dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated copd, acute bronchitis, pneumonia other than viral, primary pulmonary arterial hypertension). patients requiring hospitalization due to covid-19 or spo2 ≤ 93%. note: patients allocated to the fluvoxamine arm alone may be included if spo2 is below 94%, with no evidence of acute respiratory failure, provided that the attending physician decides to discharge the unit and continue treatment on an outpatient basis. exclusion criteria applicable to injectable medication arms: a. patients on chronic use of prednisone, prednisolone or other corticosteroids with doses > 10 mg/day equivalent to prednisone. exclusion criteria applicable to 07-day treatment arms: abnormal findings on physical examination: respiratory rate ≥ 25 sisters; blood pressure < 90/60 mmhg or > 160/100 mmhg; weight < 45 kg; recent episodes of vomiting within the last 24 hours or recurrent diarrhea or serum potassium below 3.5 meq/l. severe organ damage that requires resuscitation and ongoing treatment. chronic corticosteroid use with equivalent prednisone doses of > 40 mg/day immunosuppressive treatment in progress history of known pulmonary arterial hypertension or pulmonary fibrosis patients who have received a previous dose of sars-cov-2 vaccine use of serotonin reuptake inhibitors (all). exclusion criteria applicable to 10-day treatment arms: chronic use of serotonin reuptake inhibitors other than sertraline chronic corticosteroid use with equivalent prednisone doses of > 40 mg/day; continued use of monoamine oxidative inhibitors (maoi): phenelzine, tranylcypromine, selegiline, isocarboxazid, moclobemide. patients with severe psychiatric disorders - schizophrenia, uncontrolled bipolar disorders, major depression with suicidal ideation. pregnant or breastfeeding patients. history of severe ventricular cardiac arrhythmia (ventricular tachycardia, recovered ventricular fibrillation patients) or long qt syndrome. known history of decompensated heart failure (nyha iii or iv), recent myocardial infarction (event < 90 days of screening), unstable angina, recent coronary bypass surgery (procedure < 90 days of screening), recent stroke ( event < 90 days from screening), symptomatic carotid disease, or moderate to severe mitral or aortic stenosis. surgical procedure or hospitalization planned (for other indications) to occur during treatment or up to 5 days after the last dose of study medication. current daily and/or uncontrolled alcohol consumption, which, in the investigator's view, could compromise participation in the study. history of seizures in the last month or uncontrolled seizures. clinical history of moderate to severe hepatic impairment or hepatic cirrhosis with child-pugh c classification. patients with known serious degenerative neurological diseases and/or serious mental illnesses as assessed by the investigator. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol. any clinical conditions, including psychiatric conditions, which, in the investigator's view, could prevent the use of research drugs. known hypersensitivity and/or intolerance to fluvoxamine, budesonide, pegylated interferon lambda and fluoxetine. use of drugs which have a known interaction with fluvoxamine, budesonide, pegylated interferon lambda and fluoxetine. inability to use the drugs and formulations provided for in this research.

diagnostic test for negative sars-cov2 associated with acute flu symptoms (patient with a negative test collected early and becomes positive a few days \. later is eligible, as long as it is < 07 days since the onset of flu symptoms); patients with an acute respiratory condition compatible with covid-19 treated in the primary care network and with a decision to be hospitalized; patients with acute respiratory symptoms due to other causes; dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated copd, acute bronchitis, pneumonia other than viral, primary pulmonary arterial hypertension); patients requiring hospitalization due to covid-19 or spo2 ≤ 93%. exclusion criteria applicable to injectable medication arms: a) patients on chronic use of prednisone, prednisolone or other corticosteroid, with doses > 10 mg/day equivalent to prednisone, exclusion criteria applicable to 10-day treatment arms: chronic use of serotonin reuptake inhibitors (ssri), chronic corticosteroid use with equivalent prednisone doses of > 40 mg/day continued use of monoamine oxidase inhibitors (maoi): phenelzine, tranylcypromine, selegiline, isocarboxazid, moclobemide; patients with severe psychiatric disorders - schizophrenia, uncontrolled bipolar disorders, major depression with suicidal ideation. pregnant or breastfeeding patients; history of severe ventricular cardiac arrhythmia (ventricular tachycardia, recovered ventricular fibrillation patients) or long qt syndrome; known history of decompensated heart failure (nyha iii or iv), recent myocardial infarction (event < 90 days of screening), unstable angina, recent coronary bypass surgery (procedure < 90 days of screening), recent stroke ( event < 90 days from screening), symptomatic carotid disease, or moderate to severe mitral or aortic stenosis; surgical procedure or hospitalization planned (for other indications) to occur during treatment or up to 05 days after the last dose of study medication; current daily and/or uncontrolled alcohol consumption, which, in the investigator's view, could compromise participation in the study; history of seizures in the last month or uncontrolled seizures; clinical history of moderate to severe hepatic impairment or hepatic cirrhosis with child-pugh c classification; patients with known serious degenerative neurological diseases and/or serious mental illnesses as assessed by the investigator; inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; any clinical conditions, including psychiatric conditions, which, in the investigator's view, could prevent the use of research drugs known hypersensitivity and/or intolerance to fluvoxamine, budesonide or pegylated interferon lambda; use of drugs which have a known interaction with fluvoxamine, budesonide or pegylated interferon lambda; inability to use the drugs and formulations provided for in this research;

diagnostic test for negative sars-cov2 associated with acute flu symptoms (patient with a negative test collected early and becomes positive a few days \. later is eligible, as long as it is < 07 days since the onset of flu symptoms); patients with an acute respiratory condition compatible with covid-19 treated in the primary care network and with a decision to be hospitalized; patients with acute respiratory symptoms due to other causes; dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated copd, acute bronchitis, pneumonia other than viral, primary pulmonary arterial hypertension); patients requiring hospitalization due to covid-19 or spo2 ≤ 93%. exclusion criteria applicable to injectable medication arms: a) patients on chronic use of prednisone, prednisolone or other corticosteroid, with doses > 10 mg/day equivalent to prednisone, exclusion criteria applicable to 10-day treatment arms: chronic use of serotonin reuptake inhibitors (ssri), chronic corticosteroid use with equivalent prednisone doses of > 40 mg/day continued use of monoamine oxidase inhibitors (maoi): phenelzine, tranylcypromine, selegiline, isocarboxazid, moclobemide; patients with severe psychiatric disorders - schizophrenia, uncontrolled bipolar disorders, major depression with suicidal ideation. pregnant or breastfeeding patients; history of severe ventricular cardiac arrhythmia (ventricular tachycardia, recovered ventricular fibrillation patients) or long qt syndrome; known history of decompensated heart failure (nyha iii or iv), recent myocardial infarction (event < 90 days of screening), unstable angina, recent coronary bypass surgery (procedure < 90 days of screening), recent stroke ( event < 90 days from screening), symptomatic carotid disease, or moderate to severe mitral or aortic stenosis; surgical procedure or hospitalization planned (for other indications) to occur during treatment or up to 05 days after the last dose of study medication; current daily and/or uncontrolled alcohol consumption, which, in the investigator's view, could compromise participation in the study; history of seizures in the last month or uncontrolled seizures; clinical history of moderate to severe hepatic impairment or hepatic cirrhosis with child-pugh c classification; patients with known serious degenerative neurological diseases and/or serious mental illnesses as assessed by the investigator; inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; any clinical conditions, including psychiatric conditions, which, in the investigator's view, could prevent the use of research drugs known hypersensitivity and/or intolerance to fluvoxamine, budesonide or pegylated interferon lambda; use of drugs which have a known interaction with fluvoxamine, budesonide or pegylated interferon lambda; inability to use the drugs and formulations provided for in this research;

negative sars-cov2 test. flu-like symptom onset 08 days or more. patients with covid-19 being referred for hospitalization; > 14 days of vaccination for sars-cov-2. patients with acute respiratory conditions due to other causes; dyspnea secondary to other acute and chronic respiratory causes or infections (eg: decompensated copd, acute bronchitis, pneumonia, primary pulmonary arterial hypertension) patients with clinical evidence of moderate disease and/or hospitalization indication patients using serotonin reception inhibitors (donepezil, sertraline) use of the following medications in the last 14 days: monoamine oxide inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazide, moclobemide; alpha-1 antagonists, sotalol, clonidine, phosphodiesterase 5 inhibitors, methyldopa, prazosin, terasozin, doxazosin). use of antiretroviral agents patients with severe psychiatric disorders or major uncontrolled depression or controlled with any of the prohibited drugs (see above); pregnant or breastfeeding patients; history of severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with ventricular fibrillation recovered) or long qt syndrome; known history of symptomatic orothosthatic hypotension, syncope, postural orthostatic tachycardia syndrome (pots), neurally-mediated syncope on the last 12 months, less than 12 weeks of cerebrovascular accident, myocardial infarction, cardiovascular intervention, moderate to severe mitral or aortic stenosis. surgical procedure designed to occur during treatment or up to 04 days after the last dose of the study medication; current daily and / or uncontrolled alcoholism; history of seizures in the last month or uncontrolled medical condition; clinical history of liver cirrhosis or child-pugh c classification; patients with known severe degenerative neurological diseases and / or diseases serious mental disorders; inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; known hypersensitivity and / or intolerance to fluvoxamine, ivermectin or metformin; inability to take oral medications; inability to follow protocol-related procedures

negative sars-cov2 test. flu-like symptom onset 08 days or more. patients with covid-19 being referred for hospitalization; > 14 days of vaccination for sars-cov-2. patients with acute respiratory conditions due to other causes; dyspnea secondary to other acute and chronic respiratory causes or infections (eg: decompensated copd, acute bronchitis, pneumonia, primary pulmonary arterial hypertension) patients with clinical evidence of moderate disease and/or hospitalization indication patients using serotonin reception inhibitors (donepezil, sertraline) use of the following medications in the last 14 days: monoamine oxide inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazide, moclobemide; alpha-1 antagonists, sotalol, clonidine, phosphodiesterase 5 inhibitors, methyldopa, prazosin, terasozin, doxazosin). use of antiretroviral agents patients with severe psychiatric disorders or major uncontrolled depression or controlled with any of the prohibited drugs (see above); pregnant or breastfeeding patients; history of severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with ventricular fibrillation recovered) or long qt syndrome; known history of symptomatic orothosthatic hypotension, syncope, postural orthostatic tachycardia syndrome (pots), neurally-mediated syncope on the last 12 months, less than 12 weeks of cerebrovascular accident, myocardial infarction, cardiovascular intervention, moderate to severe mitral or aortic stenosis. surgical procedure designed to occur during treatment or up to 04 days after the last dose of the study medication; current daily and / or uncontrolled alcoholism; history of seizures in the last month or uncontrolled medical condition; clinical history of liver cirrhosis or child-pugh c classification; patients with known severe degenerative neurological diseases and / or diseases serious mental disorders; inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; known hypersensitivity and / or intolerance to fluvoxamine, ivermectin or metformin; inability to take oral medications; inability to follow protocol-related procedures

1. negative sars-cov2 test. 2. flu-like symptom onset 08 days or more. 3. patients with covid-19 being referred for hospitalization; 4. > 14 days of vaccination for sars-cov-2. 5. patients with acute respiratory conditions due to other causes; 6. dyspnea secondary to other acute and chronic respiratory causes or infections (eg: decompensated copd, acute bronchitis, pneumonia, primary pulmonary arterial hypertension) 7. patients with clinical evidence of moderate disease and/or hospitalization indication 8. patients using serotonin reception inhibitors (donepezil, sertraline) 9. use of the following medications in the last 14 days: 1. monoamine oxide inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazide, moclobemide; 2. alpha-1 antagonists, sotalol, clonidine, phosphodiesterase 5 inhibitors, methyldopa, prazosin, terasozin, doxazosin). 3. use of antiretroviral agents 10. patients with severe psychiatric disorders or major uncontrolled depression or controlled with any of the prohibited drugs (see above); 11. pregnant or breastfeeding patients; 12. history of severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with ventricular fibrillation recovered) or long qt syndrome; 13. known history of symptomatic orothosthatic hypotension, syncope, postural orthostatic tachycardia syndrome (pots), neurally-mediated syncope on the last 12 months, less than 12 weeks of cerebrovascular accident, myocardial infarction, cardiovascular intervention, moderate to severe mitral or aortic stenosis. 14. surgical procedure designed to occur during treatment or up to 04 days after the last dose of the study medication; 15. current daily and / or uncontrolled alcoholism; 16. history of seizures in the last month or uncontrolled medical condition; 17. clinical history of liver cirrhosis or child-pugh c classification; 18. patients with known severe degenerative neurological diseases and / or diseases serious mental disorders; 19. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. known hypersensitivity and / or intolerance to fluvoxamine, ivermectin or metformin; 21. inability to take oral medications; 22. inability to follow protocol-related procedures

1. negative sars-cov2 test. 2. flu-like symptom onset 08 days or more. 3. patients with covid-19 being referred for hospitalization; 4. > 14 days of vaccination for sars-cov-2. 5. patients with acute respiratory conditions due to other causes; 6. dyspnea secondary to other acute and chronic respiratory causes or infections (eg: decompensated copd, acute bronchitis, pneumonia, primary pulmonary arterial hypertension) 7. patients with clinical evidence of moderate disease and/or hospitalization indication 8. patients using serotonin reception inhibitors (donepezil, sertraline) 9. use of the following medications in the last 14 days: 1. monoamine oxide inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazide, moclobemide; 2. alpha-1 antagonists, sotalol, clonidine, phosphodiesterase 5 inhibitors, methyldopa, prazosin, terasozin, doxazosin). 3. use of antiretroviral agents 10. patients with severe psychiatric disorders or major uncontrolled depression or controlled with any of the prohibited drugs (see above); 11. pregnant or breastfeeding patients; 12. history of severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with ventricular fibrillation recovered) or long qt syndrome; 13. known history of symptomatic orothosthatic hypotension, syncope, postural orthostatic tachycardia syndrome (pots), neurally-mediated syncope on the last 12 months, less than 12 weeks of cerebrovascular accident, myocardial infarction, cardiovascular intervention, moderate to severe mitral or aortic stenosis. 14. surgical procedure designed to occur during treatment or up to 04 days after the last dose of the study medication; 15. current daily and / or uncontrolled alcoholism; 16. history of seizures in the last month or uncontrolled medical condition; 17. clinical history of liver cirrhosis or child-pugh c classification; 18. patients with known severe degenerative neurological diseases and / or diseases serious mental disorders; 19. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. known hypersensitivity and / or intolerance to fluvoxamine, ivermectin or metformin; 21. inability to take oral medications; 22. inability to follow protocol-related procedures

1. negative sars-cov2 test. 2. flu-like symptom onset 08 days or more. 3. patients with covid-19 being referred for hospitalization; 4. patients with history of sars-cov-2 vaccine shot; 5. patients with acute respiratory conditions due to other causes; 6. dyspnea secondary to other acute and chronic respiratory causes or infections (eg: decompensated copd, acute bronchitis, pneumonia, primary pulmonary arterial hypertension) 7. acute flu-like condition presenting with at least one of the criteria below: 1. respiratory rate> 28 / min; 2. sao2 <90% or <93% in nasal oxygen therapy at 10 l / min; 3. pao2 / fio2 <300 mmhg 8. patients using serotonin reception inhibitors (donepezil, sertraline) 9. use of the following medications in the last 14 days: 1. monoamine oxide inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazide, moclobemide; 2. use of iodinated contrasts during start of treatment through d14; 3. use of antiretroviral agents 10. patients with severe psychiatric disorders or major uncontrolled depression or controlled with any of the prohibited drugs (see above); 11. pregnant or breastfeeding patients; 12. history of severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with ventricular fibrillation recovered) or long qt syndrome; 13. history of diabetic ketoacidosis or clinical condition that maintains persistent acidosis 14. surgical procedure or use of contrast designed to occur during treatment or up to 04 days after the last dose of the study medication; 15. current daily and / or uncontrolled alcoholism; 16. history of seizures in the last month or uncontrolled medical condition; 17. clinical history of liver cirrhosis or child-pugh c classification; 18. patients with known severe degenerative neurological diseases and / or diseases serious mental disorders; 19. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. known hypersensitivity and / or intolerance to fluvoxamine, ivermectin or metformin; 21. inability to take oral or sublingual medications; 22. inability to follow protocol-related procedures

1. negative sars-cov2 test. 2. flu-like symptom onset 08 days or more. 3. patients with covid-19 being referred for hospitalization; 4. patients with history of sars-cov-2 vaccine shot; 5. patients with acute respiratory conditions due to other causes; 6. dyspnea secondary to other acute and chronic respiratory causes or infections (eg: decompensated copd, acute bronchitis, pneumonia, primary pulmonary arterial hypertension) 7. acute flu-like condition presenting with at least one of the criteria below: 1. respiratory rate> 28 / min; 2. sao2 <90% or <93% in nasal oxygen therapy at 10 l / min; 3. pao2 / fio2 <300 mmhg 8. patients using serotonin reception inhibitors (donepezil, sertraline) 9. use of the following medications in the last 14 days: 1. monoamine oxide inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazide, moclobemide; 2. use of iodinated contrasts during start of treatment through d14; 3. use of antiretroviral agents 10. patients with severe psychiatric disorders or major uncontrolled depression or controlled with any of the prohibited drugs (see above); 11. pregnant or breastfeeding patients; 12. history of severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with ventricular fibrillation recovered) or long qt syndrome; 13. history of diabetic ketoacidosis or clinical condition that maintains persistent acidosis 14. surgical procedure or use of contrast designed to occur during treatment or up to 04 days after the last dose of the study medication; 15. current daily and / or uncontrolled alcoholism; 16. history of seizures in the last month or uncontrolled medical condition; 17. clinical history of liver cirrhosis or child-pugh c classification; 18. patients with known severe degenerative neurological diseases and / or diseases serious mental disorders; 19. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. known hypersensitivity and / or intolerance to fluvoxamine, ivermectin or metformin; 21. inability to take oral or sublingual medications; 22. inability to follow protocol-related procedures

1. negative sars-cov2 test. 2. flu-like symptom onset 08 days or more. 3. patients with covid-19 and hospitalization referral 4. patients with acute respiratory conditions due to other causes; 5. dyspnea secondary to other acute and chronic respiratory causes or infections (eg: decompensated copd, acute bronchitis, pneumonia, primary pulmonary arterial hypertension) 6. acute flu condition presenting at least one of the criteria below: 1. respiratory rate> 28 / min; 2. sao2 <90% or <93% in nasal oxygen therapy at 10 l / min; 3. pao2 / fio2 <300 mmhg 7. patients using serotonin reception inhibitors (donepezil, sertraline) 8. use of the following medications in the last 14 days: 1. monoamine oxide inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazide, moclobemide; 2. use of iodinated contrasts during start of treatment through d14; 3. use of antiretroviral agents 9. patients with severe psychiatric disorders or major uncontrolled depression or controlled with any of the prohibited drugs (see above); 10. pregnant or breastfeeding patients; 11. history of severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with ventricular fibrillation recovered) or long qt syndrome; 12. history of diabetic ketoacidosis or clinical condition that maintains persistent acidosis 13. surgical procedure or use of contrast designed to occur during treatment or up to 04 days after the last dose of the study medication; 14. current daily and / or uncontrolled alcoholism; 15. history of seizures in the last month or uncontrolled medical condition; 16. clinical history of liver cirrhosis or child-pugh c classification; 17. patients with known severe degenerative neurological diseases and / or diseases serious mental disorders; 18. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 19. known hypersensitivity and / or intolerance to fluvoxamine, ivermectin or metformin; 20. inability to take oral medications;

1. negative sars-cov2 test. 2. flu-like symptom onset 08 days or more. 3. patients with covid-19 and hospitalization referral 4. patients with acute respiratory conditions due to other causes; 5. dyspnea secondary to other acute and chronic respiratory causes or infections (eg: decompensated copd, acute bronchitis, pneumonia, primary pulmonary arterial hypertension) 6. acute flu condition presenting at least one of the criteria below: 1. respiratory rate> 28 / min; 2. sao2 <90% or <93% in nasal oxygen therapy at 10 l / min; 3. pao2 / fio2 <300 mmhg 7. patients using serotonin reception inhibitors (donepezil, sertraline) 8. use of the following medications in the last 14 days: 1. monoamine oxide inhibitors (maois): phenelzine, tranylcypromine, selegiline, isocarboxazide, moclobemide; 2. use of iodinated contrasts during start of treatment through d14; 3. use of antiretroviral agents 9. patients with severe psychiatric disorders or major uncontrolled depression or controlled with any of the prohibited drugs (see above); 10. pregnant or breastfeeding patients; 11. history of severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with ventricular fibrillation recovered) or long qt syndrome; 12. history of diabetic ketoacidosis or clinical condition that maintains persistent acidosis 13. surgical procedure or use of contrast designed to occur during treatment or up to 04 days after the last dose of the study medication; 14. current daily and / or uncontrolled alcoholism; 15. history of seizures in the last month or uncontrolled medical condition; 16. clinical history of liver cirrhosis or child-pugh c classification; 17. patients with known severe degenerative neurological diseases and / or diseases serious mental disorders; 18. inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 19. known hypersensitivity and / or intolerance to fluvoxamine, ivermectin or metformin; 20. inability to take oral medications;